Antimicrobial resistance (AMR) is a global health problem which could make drug-resistant pathogens untreatable. Despite efforts to reduce AMR levels, threats continue to rise. One such threat is the bacterium N. gonorrhoeae; infection results in gonorrhea, a sexually transmitted disease.

Resistance to ceftriaxone, often the last antibiotic option against N. gonorrhoeae, has emerged globally. Complications arising from untreatable gonorrhea include infertility, ectopic pregnancy, HIV transmission, and neonatal keratoconjunctivitis, which leads to blindness.

The emergence of resistant pathogens calls for the development of novel antibiotics. The respiratory chain has recently garnered attention as a potential antibiotic target. Since respiratory enzymes are essential for life, the substrate binding pocket surface is similar across species; therefore, developing a competitive inhibitor for this pocket is challenging.

Another enzyme inhibitor, an allosteric inhibitor, causes a structural enzyme change, leading to inhibition of its activity. Allosteric sites are evolutionarily less conserved than substrate binding sites, potentially improving selectivity and reducing toxicity.

The team identified an allosteric inhibitory site buried inside mammalian mitochondrial heme-copper oxidases (mtHCOs), essential respiratory enzymes. The steric conformation around HCOs' binding pocket is highly conserved among bacteria and mammals; however, the existence of an additional helix in mammalian mtHcO makes their pocket surfaces distinct from bacterial HCOs. This structural difference enabled researchers to identify bacterial HCO-specific inhibitors including an antibiotic compound, Q275, that are effective against ceftriaxone-resistant N. gonorrhoeae.

Enzymes generally acquire additional subunits during molecular evolution, larger in eukaryotes than their bacterial counterparts. They could contain allostery inside the protein at the boundary of the structures between eukaryotes and bacteria, leading to the development of novel antibiotics. Any molecule essential for life and conserved among species may be a potential target.

The researchers contend that their approach can be applied to finding allosteric modulators for human disease in other therapeutic targets, potentially opening new avenues for antibiotics with novel mechanisms of action.

Researchers discover new form of undetectable antimicrobial resistance
Australian researchers have discovered a new form of antimicrobial resistance that is undetectable using traditional testing methods. Their findings may...

Excelra, HotSpot Therapeutics partner on drug discovery
Excelra is partnering with HotSpot Therapeutics to further the discovery and development of small molecule therapy candidates directed toward allosteric...

New sensor-based test could lead to fast, cheap antibiotic susceptibility testing
Scientists have developed a new method for monitoring bacterial responses to antibiotics that could enable personalized antibiotic therapies. The test...

Researchers fight drug-resistant bacteria with antibiotic 'Trojan horse'
In the latest chapter of the arms race between scientists and drug-resistant bacteria, scientists have devised an antibiotic-filled "Trojan horse" that...

Deep-learning approach easily identifies druggable protein sites
A deep-learning algorithm was able to automatically identify binding sites on proteins that could be good targets for drug candidates, according to research...

Sherlock, Binx to develop rapid CRISPR COVID-19 test
Sherlock Biosciences and Binx Health have partnered to create a rapid, point-of-care test for COVID-19 utilizing CRISPR technology.